Turing Pharmaceuticals

Vyera Pharmaceuticals (formerly Turing Pharmaceuticals) is a pharmaceutical company incorporated in Zug, Switzerland, with offices in New York City.

Drug Goes From $13.50 a Tablet to $750, Overnight

The drug, called Daraprim, was acquired in August by Turing Pharmaceuticals, a start-up run by a former hedge fund manager. Turing ...

Martin Shkreli-founded drug company files for bankruptcy - Reuters

Vyera, formerly known as Turing Pharmaceuticals, has between $10 million and $50 million in assets and between $1 million and $10 million in ...

A Timeline of the Turing Pharma Controversy - Forbes

Someone finally came along and got the whole world talking about messed up drug pricing. At least for a couple days. That someone was Martin ...

Turing Pharmaceuticals AG - The New York Times

A private equity firm is fined for misleading investors, a once-promising relationship goes sour, and a controversial pharmaceuticals company is back in the ...

A Peek Inside Turing Pharmaceuticals: 'Another $7.2 Million. Pow!'

Congressional investigators have pried loose emails showing how the company's executives anticipated huge profits from a 5000 percent drug ...

Get Rich Quick With Old Generic Drugs! The Pyrimethamine Pricing ...

The decision by Turing Pharmaceuticals to increase the price of pyrimethamine, a 62-year-old generic drug used to treat toxoplasmosis and malaria, from ...

Attorney General James Secures $40 Million From Vyera ...

Attorney General James Secures $40 Million From Vyera Pharmaceuticals, Bans Corporate Executive From Pharmaceutical ... Turing Pharmaceuticals — ...

US pharmaceutical company defends 5000% price increase - BBC

Turing Pharmaceuticals acquired the rights to Daraprim in August. CEO Martin Shkreli has said that the company will use the money it makes from ...

3. Turing Pharmaceuticals: a glimpse into controversial drug pricing.

When asked why Turing Pharmaceuticals increased the price of Daraprim, Martin Shkreli (as well as other Turing Pharma representatives) explained that the money ...

turing pharmaceuticals | PBS News

turing pharmaceuticals ... Turing Pharmaceuticals is being sued for more than $20 million by the drug maker that sold it the rights to Daraprim. By Ed Silverman ...

Daraprim and Predatory Pricing: Martin Shkreli's 5000% Hike

Turing Pharmaceuticals recently acquired the drug Daraprim and immediately raised the price over 5000%, from $13.50 to $750 a pill; ...

Shkreli ordered to return $64M, is barred from drug industry - AP News

... pharma bro no more.” Messages seeking comment were left with Shkreli's lawyers. Shkreli was CEO of Turing Pharmaceuticals — later Vyera ...

Attorney General Josh Stein Takes Legal Action Against Martin ...

Attorney General Josh Stein today took legal action against Vyera Pharmaceuticals (previously known as Turing Pharmaceuticals) and two of its former CEOs, ...

Pharma Bro No More - New York State Attorney General

... Pharmaceuticals (previously known as Turing Pharmaceuticals). The court found that Shkreli violated both federal and state laws by engaging ...

Turing Pharmaceuticals LLC - Reuters

The latest international Turing Pharmaceuticals LLC news and views from Reuters - one of the world's largest news agencies.

Turing pharma CEO recedes from public after backtracking on drug ...

Martin Shkreli, the 32-year-old founder and CEO of Turing Pharmaceuticals, took his Twitter account private Tuesday night after commenting ...

Turing Pharmaceuticals: Fair Profit or Price-Gouging in the Drug ...

Product Description ... This case examines how a drug price increase by one small company, Turing Pharmaceuticals, became the focal point of a controversy that ...

CEO: 5000-percent drug price hike "not excessive at all" - CBS News

Turing Pharmaceuticals got control of a crucial infection treatment drug called Daraprim in August, and immediately raised the price from ...

Convicted 'Pharma Bro' Shkreli's Vyera Files for Bankruptcy

Vyera, formerly Turing Pharmaceuticals, was driven to bankruptcy by mounting generic pressure, declining profits and a Federal Trade ...